Business
Bruker Enables High-Throughput Multiplex HTS on Sierra SPR Platform
Sierra Surface Plasmon Resonance (SPR) Pro Series for High-Throughput Screening (HTS) Innovative Sierra SPR-32 Pro allowing multiplex HTS for insights into
About this update from Bruker Corporation
[{"type":"text","content":"\nSierra Surface Plasmon Resonance (SPR) Pro Series for High-Throughput Screening (HTS)\n\n\nInnovative Sierra SPR-32 Pro allowing multiplex HTS for insights into kinetics with no compromise in sensitivity and nature of samples\n\n\nSPR insights into molecular interactions by label-free HTS in support of drug discovery\n\n\n BOSTON--(BUSINESS WIRE)--\nAt the SLAS2022 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) is announcing a multiplexed assay taking high-throughput screening with SPR to the next level. The innovative microfluidic system of the Bruker Sierra SPR-32 Pro provides a unique 8x4 array for parallel readout of 32 measurement sensor spots per injection at exceptional robustness. This configuration offers high throughput while maintaining flexibility for the development of both, biologics and small molecule drug candidates, e.g., for testing one antigen against 31 antibodies, to 8 small molecules against 3 target proteins with a single reference per channel.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220207005150/en/The Bruker Sierra SPR-32 Pro offers throughput-optimized assay set-ups for the development of both biologics and small molecule drug candidates. Single analytes like an antigen can be simultaneously tested against up to 31 capture antibodies (A). The same platform also allows to test up to 8 analytes against one to three targets with a single experiment (B). The latter set-up coupled with automation provides industry-leading throughput for SPR. (Graphic: Business Wire)\nBruker impressively demonstrated the multiplexing capabilities of the Sierra SPR-32 Pro platform with a selectivity assay, typical for lead development stages, and a screening assay against a set of carbonic anhydrases, a protein family with a high degree of similarity. These challenging examples typically require tedious repetitions of the same assay for each target protein, slowing down the drug development process. The multiplexing capabilities of the Sierra SPR-32 Pro reduces measurement time by up to threefold. Bruker’s highly sensitive SPR detection enables measurements at high molecular weight differences between analyte and target of 10-3, supporting even fragment-based drug design.\n\nMoreover, Bruker has developed automated 24/7 SPR plat...